Interim Report 1st half-year 2014/15 (1 June 2014 - 30

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim Report 1st half-year 2014/15 (1 June 2014 - 30 November 2014)

Q2 HIGHLIGHTS

“The Group’s financial results for the second quarter were adversely impacted by the ramp-up issues in production and other supply-chain issues, which caused a delayed launch of key products, and higher production costs than previously anticipated. The combination of a continued strengthening of the product portfolio in AV and B&O PLAY, a more stable production rhythm, and further expansion of the distribution, as well as a stable development in Automotive, are expected to result in a strong second half of the year, with significant revenue growth and improved profitability compared to last year. It will however not be enough to compensate for the poor performance in the first half of the financial year”, says CEO Tue Mantoni.

  • The Group’s revenue was DKK 759 million for the second quarter of the 2014/15 financial year compared to revenue of DKK 822 million in the same period last year, corresponding to a decrease of 8 per cent.
  • The B2C business recorded revenue of DKK 570 million in the second quarter of the 2014/15 financial year compared to DKK 632 million in the same period last year. Ramp-up issues in the production have, to a larger extent than anticipated, adversely impacted the timing of key product launches.
  • B2C revenue decreased across all regions compared to the same quarter last year. Europe and Rest of World decreased by 10 per cent, and North America and BRIC decreased by 16 and 28 per cent respectively. The decrease in BRIC was due to delayed product launches in China and continued high uncertainty in the Russian market.
  • At the end of the second quarter, there were 541 B1 shops across the world against 538 at the end of the first quarter. It was the first quarter since 2007 with a net increase in the number of stores.
  • The B2B business recorded revenue of DKK 183 million in the second quarter of the 2014/15 financial year compared to revenue of DKK 194 million in the same period last year. Automotive revenue was, as expected, back on par with the level of last year after a very weak first quarter. ICEpower decreased by 29 per cent.
  • The Group’s gross margin for the second quarter of the 2014/15 financial year was 34.2 per cent compared to 42.7 per cent in the same period last year and 36.2 per cent in the first quarter of the current financial year. The lower margin was mainly a result of a high TV share in the AV segment and ramp-up issues in the production relating to the BeoVision Avant.
  • Capacity costs were DKK 355 million in the second quarter, compared to DKK 321 million in the second quarter last year due to a lower level of capitalization of R&D costs and higher distribution- and marketing costs.
  • Earnings before interest and tax for the second quarter of the 2014/15 financial year were negative DKK 95 million compared to positive DKK 31 million in the same quarter last year. The impact from capitalization and amortization on earnings before interest and tax was negative DKK 23 million compared to the same quarter last year.
  • Free cash flow in the second quarter was negative DKK 40 million compared to negative DKK 52 million in the same period last year. The Group’s net working capital improved to DKK 724 million from DKK 777 at the end of the first quarter. This improvement partially mitigated the adverse effect from the worse than expected negative net result on free cash flow.
  • The Group’s total revenue for the first six months of the 2014/15 financial year was DKK 1,330 million against DKK 1,388 million last year, corresponding to a decrease of 4 per cent. Earnings before interest and tax for the first six months of the 2014/15 financial year were negative DKK 224 against negative DKK 34 million last year. Free cash flow in the first six months of the 2014/15 financial year was negative DKK 281 million compared to negative DKK 121 million last year.
  • After the end of reporting period Bang & Olufsen announced the launch of BeoSound Moment, BeoVision Avant 75” and BeoPlay H8.
  • As previously disclosed in company announcement 14.23 from 22 December 2014, the company has revised the outlook for 2014/15. The topline guidance of a high single digit growth is maintained. The guidance for earnings before interest and tax (EBIT) is revised from the expectation of an improving EBIT margin to a negative EBIT margin for the year. EBIT in the second half of the financial year is expected to be positive, however not sufficient to compensate for the shortfall in the first half of the financial year. Free cash flow in the second half of the financial year is expected to be in the range of DKK 50 million to DKK 100 million through a combination of earnings and a continuous reduction in net working capital.
  • As disclosed in company announcement 14.23, the Board of Directors and Executive Management has initiated a review to identify strategic and structural options to increase scale and further reduce complexity.

Any enquiries about this announcement can be addressed to:

CEO, Tue Mantoni, tel.: +45 9684 5000

CFO, Anders Aakær Jensen, tel.: +45 9684 5000

Investors, Claus Højmark Jensen, tel.: +45 2325 1067

Press, Jan Helleskov, tel.: +45 5164 5375

A webcast will be hosted on 20 January 2015 at 10.00 CET. Access to the webcast is obtained through our home page www.bang-olufsen.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 125

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 116

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 221

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 96

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 137

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 167

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 135

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 253

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 44

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

We Energies Recognized for Exceptional Reliability Standards

Updated Category News Views 172

We Energies Celebrated for Excellence in Reliability MILWAUKEE / We Energies has recently been honored with the esteemed 2025 ReliabilityOne® Award, recognizing its superior performance in delivering reliable electric service. This accolade is a testament to the dedication and expertise of its workforce, as well as the strategic investments the company has made to...

Continue Reading
MicroStrategy Options Activity: Insights and Market Trends

Updated Category News Views 59

What Recent Options Activity Says About MicroStrategy Options flow often hints at how the crowd feels before price moves show it. Lately, the tone around MicroStrategy (MSTR) has leaned bearish, a point worth noting if you’re weighing your own trades. The signal isn’t subtle: activity has picked up sharply, and that surge alone can draw in traders who watch sentiment...

Continue Reading
Viactiv Expands Wellness Line with New Chews and Powder

Updated Category News Views 16

Viactiv Expands Beyond Calcium Forget just bone health; Viactiv is stepping up its game. They've gone beyond their trusty calcium chews with something new that targets women’s wellness in a broader sense. Meet the newcomers: Viactiv® CoQ10 CARDIO Complete Soft Chews and Viactiv® Magnesium Glycinate Powder. Ain't that a mouthful? But seriously, these are designed for...

Continue Reading
Rathbones Group Plc's Significant Position in Warpaint London

Updated Category News Views 107

Key Disclosure of Rathbones Group Plc In the financial landscape, transparency is of utmost importance, especially when significant interests in securities come to light. Rathbones Group Plc has provided a crucial disclosure as they maintain an interest in relevant securities of Warpaint London Plc, representing over 1% of their shares. This type of disclosure aligns with...

Continue Reading
Insights into Tryg A/S Q4 2024 Performance and Expectations

Updated Category News Views 260

Overview of Tryg A/S Q4 2024 Newsletter As the end of the year approaches, Tryg A/S is gearing up for a busy period of financial disclosures and investor engagement. In the week commencing mid-December, Tryg will conduct several pre-close analyst calls and meetings. This initiative is designed to prepare stakeholders ahead of the crucial Q4 2024 results release, which is...

Continue Reading